MGO One Seven LLC Purchases 1,389 Shares of Zimmer Biomet Holdings, Inc. $ZBH

MGO One Seven LLC lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 59.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,717 shares of the medical equipment provider’s stock after acquiring an additional 1,389 shares during the quarter. MGO One Seven LLC’s holdings in Zimmer Biomet were worth $339,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Zimmer Biomet by 0.7% in the first quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock valued at $2,609,130,000 after acquiring an additional 166,763 shares in the last quarter. Dodge & Cox raised its holdings in shares of Zimmer Biomet by 2.3% in the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after acquiring an additional 446,018 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Zimmer Biomet by 236.0% in the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after purchasing an additional 3,208,596 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after purchasing an additional 1,488,918 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Zimmer Biomet by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock worth $233,009,000 after purchasing an additional 58,060 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $102.00 on Monday. The business’s 50 day moving average price is $101.74 and its 200 day moving average price is $97.68. The firm has a market cap of $20.21 billion, a P/E ratio of 24.82, a P/E/G ratio of 2.35 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $114.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of recent research reports. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Evercore ISI reduced their target price on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a report on Tuesday, October 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a report on Thursday, September 18th. Finally, Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $111.94.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.